News
ADRX
13.23
-0.45%
-0.06
Weekly Report: what happened at ADRX last week (1026-1030)?
Weekly Report · 5d ago
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:12
Weekly Report: what happened at ADRX last week (1019-1023)?
Weekly Report · 10/26 10:35
TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating
Benzinga · 10/20 14:06
ADARx Pharmaceuticals Initiated at Overweight by JP Morgan
Dow Jones · 10/20 12:58
ADARx Pharmaceuticals Price Target Announced at $38.00/Share by JP Morgan
Dow Jones · 10/20 12:58
ADARx Pharmaceuticals Price Target Announced at $35.00/Share by UBS
Dow Jones · 10/20 12:36
This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 10/20 12:31
UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35
Benzinga · 10/20 12:27
ADARx Pharmaceuticals initiated with an Outperform at LifeSci Capital
TipRanks · 10/20 11:00
ADARx Pharmaceuticals Price Target Announced at $32.00/Share by Morgan Stanley
Dow Jones · 10/20 10:04
Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32
Benzinga · 10/20 09:54
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Incyte (INCY) and ADARx Pharmaceuticals (ADRX)
TipRanks · 10/20 09:20
ADARx Pharmaceuticals initiated with a Buy at TD Cowen
TipRanks · 10/20 09:05
ADARx Pharmaceuticals initiated with an Overweight at Morgan Stanley
TipRanks · 10/20 09:00
ADARx Pharmaceuticals initiated with a Buy at UBS
TipRanks · 10/20 09:00
Opening Day: Biotech duo City Therapeutics, Iambic make debuts
TipRanks · 10/19 16:00
Weekly Report: what happened at ADRX last week (1012-1016)?
Weekly Report · 10/19 10:35
Weekly Report: what happened at ADRX last week (1005-1009)?
Weekly Report · 10/12 10:42
Primary Markets Group September 2026 U.S. IPO Update
Seeking Alpha · 10/06 05:00
More
Webull provides a variety of real-time ADRX stock news. You can receive the latest news about ADARx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ADRX
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. siRNA, or small interfering RNA, therapeutics represent a significant advancement in precision medicine by addressing diseases at the genetic level (mRNA or RNA) while avoiding permanent alterations to a patient’s genome (DNA). Its hepatic-targeted programs include Agazisiran, Onvuzosiran, and ADX-626. Its extrahepatic-targeted programs include ADX-077 and ADX-199. ADX-077 is designed to reduce body weight and fat while preserving lean mass. ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.